Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | HTT | P42858 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.59 |
| ▸ | MEN1 | O00255 | 5/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | ATM | Q13315 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.55 |
| ▸ | DRD4 | P21917 | 1/20 | 0.54 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | GPR183 | P32249 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21044044 | 0.86 | KMT2A (0.62) | ALDH1A1KDM4ELMNAHTTKMT2A | |
| SCHEMBL16226380 | 0.83 | ALDH1A1 (0.81) | ALDH1A1KDM4ELMNAHTTKMT2A | |
| Hydrochloric Acid SCHEMBL9052930 | 0.82 | ALDH1A1 (0.60) | ALDH1A1KDM4ELMNAHTTKMT2A | |
| SCHEMBL27597072 | 0.78 | ALDH1A1 (0.64) | ALDH1A1KDM4ELMNAKMT2AMEN1 | |
| SCHEMBL8261374 | 0.78 | ALDH1A1 (0.70) | ALDH1A1KDM4ELMNAHTTKMT2A | |
| SCHEMBL27615799 | 0.78 | MEN1 (0.64) | ALDH1A1KDM4ELMNAHTTKMT2A | |
| SCHEMBL3322986 | 0.77 | ALDH1A1 (0.66) | ALDH1A1KDM4ELMNAHTTKMT2A | |
| SCHEMBL3158860 | 0.77 | ALDH1A1 (0.68) | ALDH1A1KDM4ELMNAKMT2AATM | |
| SCHEMBL20765529 | 0.76 | ALDH1A1 (0.74) | ALDH1A1KDM4ELMNAHTTKMT2A | |
| SCHEMBL3262128 | 0.76 | ALDH1A1 (0.96) | ALDH1A1KDM4ELMNAHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | NOVARTIS AG (CH) | 2010-05-20 | — | — | US | disclosed |
| EP-2142535-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis Ag (CH) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008119741-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | MDM4, TP53, MDM2 | ALDH1A1 2589/4885KDM4E 920/4885LMNA 2574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.